Logos Global Management »

Tourmaline Bio shares owned by Logos Global Management

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by Logos Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $7.4M 284k 26.18

More positions owned by Logos Global Management

Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Sarepta Therapeutics Call Option (SRPT)
Ideaya Biosciences (IDYA)
Argenx Se Sponsored Adr (ARGX)
Olema Pharmaceuticals (OLMA)
Immunovant (IMVT)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Rayzebio
Ambrx Biopharma
Karuna Therapeutics Ord
Immunocore Hldgs Ads (IMCR)
Dyne Therapeutics (DYN)
Morphosys Sponsored Ads Call Option (MOR)

View all positions for Logos Global Management

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
Jennison Associates
QVT Financial
Braidwell
venBio Select Advisor
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Qiming U.S. Ventures Management
Vivo Capital
Nantahala Capital Management
Balyasny Asset Management
Logos Global Management
Susquehanna International
Artal Group
AlphaCentric Advisors

View all funds holding Tourmaline Bio